0000899243-20-021957.txt : 20200810 0000899243-20-021957.hdr.sgml : 20200810 20200810192539 ACCESSION NUMBER: 0000899243-20-021957 CONFORMED SUBMISSION TYPE: 4 PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20200806 FILED AS OF DATE: 20200810 DATE AS OF CHANGE: 20200810 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: Rohlen Douglas CENTRAL INDEX KEY: 0001306344 FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 001-38533 FILM NUMBER: 201090761 MAIL ADDRESS: STREET 1: 3600 HOLLY LANE NORTH, SUITE 40 CITY: PLYMOUTH STATE: MN ZIP: 55447 FORMER NAME: FORMER CONFORMED NAME: Rohlen Duke DATE OF NAME CHANGE: 20041019 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: Eidos Therapeutics, Inc. CENTRAL INDEX KEY: 0001731831 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 463733671 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 BUSINESS ADDRESS: STREET 1: 101 MONTGOMERY STREET, SUITE 2550 CITY: SAN FRANCISCO STATE: CA ZIP: 94104 BUSINESS PHONE: 650-391-9740 MAIL ADDRESS: STREET 1: 101 MONTGOMERY STREET, SUITE 2550 CITY: SAN FRANCISCO STATE: CA ZIP: 94104 4 1 doc4.xml FORM 4 SUBMISSION X0306 4 2020-08-06 0 0001731831 Eidos Therapeutics, Inc. EIDX 0001306344 Rohlen Douglas C/O EIDOS THERAPEUTICS, INC. 101 MONTGOMERY STREET, SUITE 2000 SAN FRANCISCO CA 94104 1 0 0 0 Restricted Stock Units 2020-08-06 4 A 0 4526 0.00 A Common Stock 4526 4526 D Stock Option (Right to Buy) 41.42 2020-08-06 4 A 0 21447 0.00 A 2030-08-05 Common Stock 21447 21447 D Each Restricted Stock Unit ("RSU") represents a contingent right to receive one share of the Issuer's Common Stock. The shares of Common Stock underlying the RSUs vest in three annual installments after the date of grant, subject to the Reporting Person's continued service on the Issuer's board of directors as of each vesting date. The stock option shall vest in three annual installments after the date of grant, subject to the Reporting Person's continued service on the Issuer's board of directors as of each vesting date. /s/ Franco Valle, as Attorney-in-Fact 2020-08-10